NCT02167451

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Children's Hospital Medical Center, Cincinnati · Academic / Other
• Sex: All
• Age: 5 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose is to determine if the addition of Maraviroc to a standard transplant regimen will reduce the incidence of graft versus host disease in children and young adults after a stem cell transplant.

Detailed description

In the first stage, drug levels will be obtained to establish appropriate dosing. In the second stage of the study the investigators will study the effects of using Maraviroc in these patients.

Conditions

• Diagnoses That Require Stem Cell Transplant
• Graft Versus Host Disease (GVHD)

Interventions

Type	Name	Description
DRUG	Maraviroc

Timeline

• Start date: 2014-07-01
• Primary completion: 2018-09-01
• Completion: 2018-09-01
• First posted: 2014-06-19
• Last updated: 2020-03-10
• Results posted: 2020-03-10

Locations

1 site across 1 country: United States